Streetbeat News

Partnerships

LXRX

Lexicon Pharmaceuticals announced that INPEFA has received coverage from Express Scripts on its basic and high performance formularies for commercially insured patients.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 1:04 pm

NTDOY

WSM

Pottery Barn Teen, a division of Williams-Sonoma, Inc. (WSM), has announced a collaboration with the Super Mario franchise, owned by Nintendo Co., Ltd. (NTDOY). The exclusive collection of décor, textiles, and accessories inspired by the Mushroom Kingdom is now available at Pottery Barn Teen.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:58 pm

ALDX

CLLS

TGTX

Cellectis (CLLS) has announced strategic collaboration and investment agreements with AstraZeneca. Aldeyra Therapeutics (ALDX) has entered into an exclusive option agreement with AbbVie for the license to develop and commercialize Reproxalap. TG Therapeutics (TGTX) reported GAAP EPS of $0.73, beating estimates by $0.56, and revenue of $165.82M, beating by $102.48M.

Portfolio Pulse from ryanfaloona@benzinga.com

November 01, 2023 | 12:45 pm

STRR

Star Equity Holdings' subsidiary, KBS Builders, has won a $1.9 million initial contract to manufacture 12 modules for an affordable housing project in rural Maine. The first phase of the project will provide 18 affordable rental units, expected to be ready by early spring 2024. The project is part of a wider acceptance of modular manufacturing in local government organizations.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:41 pm

HSBC

RGTI

Rigetti UK Limited, a subsidiary of Rigetti Computing, Inc. (NASDAQ:RGTI), has been awarded an Innovate UK grant to enhance quantum machine learning methods for anti-money laundering detection. The consortium, which includes HSBC, the Quantum Software Lab at the University of Edinburgh, and the National Quantum Computing Centre, aims to improve current machine learning algorithms. The project, which began on September 1, 2023, will last 18 months.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:40 pm

ATRA

Atara Biotherapeutics has expanded its global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel), a T-cell immunotherapy. The deal includes licensing commercialization rights to Tab-cel in the US and all remaining markets. Atara will receive up to $640 million, significant double-digit tiered royalties on net sales, and funding for Tab-cel global development costs. The partnership extends Atara's cash runway into Q3 2025. Atara also announced its Q3 2023 financial results, with cash, cash equivalents, and short-term investments totaling $102.4 million as of September 30, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:34 pm

PLTR

AI security firm CalypsoAI has partnered with Palantir Technologies Inc. (NYSE:PLTR) to use Palantir's FedStart program. CalypsoAI's security platform will be made available to government agencies through FedStart, providing an accredited environment for AI security and other application deployments. The partnership will allow for rapid adoption of CalypsoAI's solutions by a greater number of government customers.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:32 pm

FRSX

Foresight Autonomous Holdings Ltd. (FRSX) is focusing on defense, industrial vehicles, and Eye-Net Mobile initiatives in the short term. The company has signed several agreements and achieved milestones in these sectors, including a $4 million deal with Elbit Systems and a $51 million deal with SUNWAY-AI Technology. Foresight is also pursuing projects in the automotive industry, with partnerships with Hitachi Astemo and ZF Friedrichschafen. The company's Eye-Net subsidiary has partnered with SoftBank and received an order from a leading Japanese vehicle manufacturer.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:28 pm

CVAC

GSK

CureVac N.V. (NASDAQ:CVAC) has announced progress in its Phase 2 clinical vaccine development programs for COVID-19 and seasonal flu, conducted in collaboration with GSK. The COVID-19 Phase 2 study, which compares mono- and bivalent vaccine candidates against a licensed comparator COVID-19 vaccine, has been fully enrolled. The first participant has been dosed in the seasonal flu Phase 2 part of a combined Phase 1/2 study. Interim Phase 2 data for both programs are expected in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:27 pm

CLLS

PAYC

PSTV

WE

Several stocks are experiencing significant pre-market trading movements. Cellectis S.A. (CLLS) surged 152% following strategic collaboration and investment agreements with AstraZeneca. Plus Therapeutics, Inc. (PSTV) rose 11.3% after announcing third-quarter financial results and a share repurchase program. On the downside, WeWork Inc. (WE) dipped 37.3% amid reports of a planned Chapter 11 bankruptcy filing. Paycom Software, Inc. (PAYC) fell 37.1% after reporting worse-than-expected third-quarter sales results and issuing below-estimate FY23 revenue guidance.

Portfolio Pulse from Lisa Levin

November 01, 2023 | 12:07 pm